The Descale Study aims to: 1. Look at the prescribing trends of opioids and the scale of long-term use following surgery within East Kent (United Kingdom) 2. Carry out a feasibility study to: * see if clinical pharmacists can support patients following surgery to manage their post-surgical pain safely and prevent long-term opioid use * calculate how much it costs the National Health Service (NHS) * see how the patients experienced the intervention For Aim 1, historic records of patients who have had surgery and were discharged on opioids will be reviewed. Data collected will include type and strength of pain-relieving medication prescribed; type of surgery; number of additional opioid prescriptions following discharge; use of medical services (e.g., General Practice appointments, physiotherapy); and patient demographics. For Aim 2, clinical pharmacists will carry out early high-risk medication safety reviews to ensure that patients have their pain managed safely. Investigators will collect key data from patients receiving the clinical pharmacist intervention to see how it affected opioid use, costs and healthcare use. Patients who took part in the study will be invited to participate in an interview and will be asked what they know about opioids and the health risks, and their experiences of the intervention.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Determination of the fidelity of an early opioid deprescribing intervention led by trained clinical pharmacists in primary care and their role in the wider medicine's optimisation programme.
Timeframe: Month 3
Determination of the fidelity of an early opioid deprescribing intervention led by trained clinical pharmacists in primary care and their role in the wider medicine's optimisation programme.
Timeframe: Month 3
Determination of the fidelity of an early opioid deprescribing intervention led by trained clinical pharmacists in primary care and their role in the wider medicine's optimisation programme.
Timeframe: Month 3
Determination of the fidelity of an early opioid deprescribing intervention led by trained clinical pharmacists in primary care and their role in the wider medicine's optimisation programme.
Timeframe: Month 3
Determination of the barriers/enablers that affect the delivery of the intervention from the perspective of the NHS stakeholders.
Timeframe: Up to 3 months after final follow up
Determination of the barriers/enablers that affect the delivery of the intervention from the perspective of the surgical patient.
Timeframe: Up to 3 months after final follow up
Determination of the barriers/enablers that affect the delivery of the intervention from the perspective of the surgical patient.
Timeframe: Up to 3 months after final follow up
Determination of the barriers/enablers that affect the delivery of the intervention from the perspective of the surgical patient.
Timeframe: Up to 3 months after final follow up
Determination of the barriers/enablers that affect the delivery of the intervention from the perspective of the surgical patient.
Timeframe: Up to 3 months after final follow up
Determination of the barriers/enablers that affect the delivery of the intervention from the perspective of the surgical patient.
Timeframe: Up to 3 months after final follow up
Establishment of the cost of delivering the intervention from the health/social care provider (NHS), perspective.
Timeframe: Up to 3 months after the end of recruitment